**Name of journal: World Journal of Hepatology**

**ESPS Manuscript NO: 15583**

**Columns: REVIEW**

**“Weighing the risk”: Obesity and outcomes following liver transplantation**

Reichman TW *et al*. LTx in the obese

Trevor W Reichman, George Therapondos, Maria-Stella Serrano, John Seal, Rachel Evers-Meltzer, Humberto Bohorquez, Ari Cohen, Ian Carmody, Emily Ahmed, David Bruce, George E Loss

**Trevor W Reichman, George Therapondos, Maria-Stella Serrano, John Seal, Rachel Evers-Meltzer, Humberto Bohorquez, Ari Cohen, Ian Carmody, Emily Ahmed, David Bruce, George E Loss**, Multi Organ Transplant Institute, Ochsner Medical Center, 1514 Jefferson Highway, New Orleans, LA 70121, United States

**Author contributions:** Reichman TW and Meltzer R collected and analyzed papers for the review; Reichman TW, Therapondos G and Serrano MS wrote the paper; Seal J, Bohorquez H, Cohen A, Carmody I, Ahmed E, Bruce D and Loss GE were responsible for the critical revision of the manuscript.

**Conflict-of-interest:** The authors have no conflicts of interest related to this manuscript.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Trevor W Reichman MD, PhD,** Multi-organ Transplant Institute, Ochsner Medical Center, New Orleans, LA 70121, United States. treichman@ochsner.org

**Telephone:** +1-504-8423925

**Fax:** +1-504-8425746

**Received:** November 29, 2014

**Peer-review started:** November 29, 2014

**First decision:** January 20, 2015

**Revised:** February 23, 2015

**Accepted:** April 10, 2015

**Article in press:**

**Published online:**

**Abstract**

Obesity is on the rise worldwide. As a result, unprecedented rates of patients are presenting with end stage liver disease in the setting of non-alcoholic fatty liver disease (NAFLD) and are requiring liver transplantation. There are significant concerns that the risk factors associated with obesity and the metabolic syndrome might have a detrimental effect on the long term outcomes following liver transplantation. In general, short term patient and graft outcomes for both obese and morbidly obese patients are comparable with that of non-obese patients, however, several studies report an increase in peri-operative morbidity and increased length of stay. Continued studies documenting the long-term outcomes from liver transplantation are needed to further examine the risk of recurrent disease (NAFLD) and also further define the role risk factors such cardiovascular disease might play long term. Effective weight reduction in the post liver transplant setting may mitigate the risks associated with the metabolic syndrome long-term.

**Key words:** Liver transplantation; Obesity; Morbid obesity; Non-alcoholic steatohepatitis; Non-alcoholic fatty liver disease; End stage liver disease; Cirrhosis

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Cirrhosis in the setting of obesity especially from non-alcoholic fatty liver disease is quickly becoming one of the leading indications for liver transplantation. These patients present unique challenges both at the time of transplant and long term secondary to chronic illnesses associated with the metabolic syndrome. Outcomes following liver transplantation and management of these patients will be discussed in light of the current available literature.

Reichman TW, Therapondos G, Serrano MS, Seal J, Evers-Meltzer R, Bohorquez H, Cohen A, Carmody I, Ahmed E, Bruce D, Loss GE. “Weighing the risk”: Obesity and outcomes following liver transplantation. *World J Hepatol* 2015; In press

**Introduction**

Obesity or the excessive accumulation of body fat contributes to a host of chronic health problems. Obesity is defined by a body mass index greater then 30 whereas severe obesity, morbid obesity and super obesity are defined by a body mass index (BMI) ≥ 35, 40, and 50, respectively[1]. Obesity rates have continued to sore throughout the world as populations continue to adopt a more “Western” type of lifestyle. A diet of highly processed, refined foods, fat, and red meats has also been linked to increase rates of cardiovascular disease and cancer. Based on recent statistics, it is estimated that greater then 2.1 billion people in the world are either overweight or obese[2]. In the United States, there are approximately 30 million people who are overweight equaling greater than 30% of the population[2].

Obesity is associated with the clinical condition known as the metabolic syndrome that includes hypertension, hyperlipidemia, hyperglycemia, and increased abdominal fat deposition[3]. In addition to obesity, insulin resistance has also been found to be associated with the metabolic syndrome[4]. Individuals with a diagnosis of metabolic syndrome are at increased risk for cardiovascular events, stroke, diabetes, and chronic liver disease.

The natural course of chronic liver disease is progression to cirrhosis and end stage liver disease (ESLD) if the inciting factor(s) is not controlled. ESLD leads to portal hypertension and a host of other complications including gastrointestinal bleeding, encephalopathy, jaundice, ascites, malnutrition, and hepatocellular cancer (HCC). Although there are multiple causes of chronic liver disease and cirrhosis (*e.g.*, viral hepatitis, autoimmune hepatitis, cholestatic liver diseases, excessive alcohol consumption), the most common cause of chronic liver disease in the United States is now non-alcoholic fatty liver disease (NAFLD) or its more aggressive form, non-alcoholic steatohepatitis (NASH)[5].

Obesity and its associated complications is thought to have a significant impact on post-operative outcomes and survival after surgical procedures. The allocation of health resources and the expense associated with caring for obese patients continues to be controversial especially in light of the current changing health care landscape. Nowhere is this more true than in the field of liver transplantation in which there is not only an obligation to provide cost effective care but also the responsibility of allocating a scarce resource.

***NAFLD, NASH, and obesity***

NAFLD is thought to be the hepatic manifestation of the metabolic syndrome.NAFLD encompasses a spectrum of clinicopathologic disease ranging from hepatic steatosis (in the absence of significant alcohol consumption) to the more aggressive form NASH in which fatty deposition and necroinflammation are present. Pathologically, NASH is characterized by macrovesicular steatosis, ballooning degeneration with or without Mallory bodies, and lobular or portal inflammation, with or without fibrosis[6]. The majority of patients with NAFLD have a benign course and many have stable fatty liver disease. NASH is thought to result from a two-hit insult in which accumulation of fat is the first step but an additional stressor is necessary in order to lead to progressive liver damage and NASH[7]. Interestingly, there also appears to be a genetic predisposition to developing NAFLD and NASH[8]. In addition, there are racial differences observed in the prevalence of NAFLD in the United States with the highest prevalence found in Hispanics, followed by Caucasians, and then African-Americans[9-11].

It is estimated that greater than 25% of patients with NASH will develop progressive fibrosis over time with approximately 10%-20% of patients eventually developing advanced fibrosis or cirrhosis[12]. Clinical risk factors for progression of fibrosis include insulin resistance and hypertension[13]. NASH likely accounts for a large portion of cases that were previously labeled as cryptogenic cirrhosis especially those cases of cirrhosis that occur in the setting of obesity, diabetes, and cardiovascular disease. Further support for the link between NASH and cryptogenic cirrhosis comes from the fact that patients transplanted for cryptogenic cirrhosis have a high prevalence of NAFLD and NASH in their post transplant grafts[14].

The incidence of NAFLD in Western countries is estimated to be between 20%-30%[15]. Currently in the United States, NAFLD and NASH are the leading causes of chronic liver disease and NAFLD is estimated to effect approximately 30% of the general United States population and up to 90% of people with morbid obesity. NASH is thought to affect about 5%-13% of the general population, and studies have shown the presence of NASH in 31% of patients with a clinical diagnosis of NAFLD on ultrasound[9].

***NASH in pediatric patients***

The obesity epidemic has not spared the pediatric population in the world. Typically thought of as a disease of adulthood, obesity rates and the incidence of NAFLD and NASH have skyrocketed in the pediatric population. Like adults, NAFLD now is the most common cause of chronic liver disease in children and adolescents[16]. An autopsy study found that 9.6% of the American population aged 2-19 years old have NAFLD, and the percentage increased to 38% among those who were obese[17]. NAFLD appears to be more prevalent in the older adolescents as compared to younger children and is also more common in boys (ratio of 2:1)[18]. NAFLD is more prevalent in the Mexican communities and also in children from Asian-Indian and Asian-American descent[19,20]. Rates in Asian patients are thought to potentially be due to increased rates of insulin resistance and visceral adiposity[19]. The long-term outcomes of pediatric NAFLD are not well known and are actively being investigated. A recent study, however, suggests that biopsies from adolescents with NAFLD have significantly higher incidence of NASH, hepatocyte injury scores and fibrosis when compared to a similar group of adults. The authors concluded that adolescents with severe obesity have more advanced liver damage and more severe systemic inflammation than adults suggesting differences in NAFLD etiologies and more aggressive disease progression in the young obese population[21].

The data on NAFLD/NASH progression and the need for liver transplantation are scant. However, in one study, 66 children with NAFLD were followed for up to 20 years and 2 of these children underwent liver transplantation for decompensated cirrhosis. In both of these children, NAFLD recurred in the allograft with one case progressing to cirrhosis requiring retransplantation[22]. Further studies are needed to identify those children that are at higher risk for progression of NAFLD to NASH and ultimately might require liver transplantation.

***Obesity and HCC***

One of the major indications for liver transplantation is HCC, especially when the tumor is multifocal or when it occurs in the setting of chronic liver disease. Obesity has been identified in several studies as a clear risk factor for the development of HCC[23-25]. In the case of NAFLD, it is estimated that HCC occurs in up to 27% of patients with cirrhosis, but even patients without NASH are at risk for developing HCC[26]. The etiology of HCC in NAFLD and NASH is thought to be related to chronic inflammation and repeated injury to hepatocytes from the accumulation of fat in the liver. Interestingly, recurrence-free survival in patients with HCC in the setting of NASH appear to be significantly better then in the setting of hepatitis C (HCV) for both resection and liver transplantation[27,28].

**Outcomes following Liver Transplantation in Obese Individuals**

Early reports of liver transplantation in obese recipients demonstrated mixed outcomes perhaps because of small sample sizes. Studies have also included heterogeneous groups of recipients; some focus simply on obese patients (BMI ≥ 30) whereas other studies differentiate between obese patients and morbidly obese patients (BMI ≥ 40). Initial single center reports showed equivalent short term survival rates for obese and severely obese patients with some centers also documenting higher complication rates (especially wound infections) and higher health care costs for transplantation[29-32]. More recently, there have been several single center and multi-center studies that have focused on preoperative and long outcomes following liver transplantation.

***Outcomes of obese patients: Peri-operative morbidity and length of stay***

Liver transplant recipients have a significant survival advantage as compared to patients that continue on the waiting list regardless of their BMI at the time of transplant[33,34]. Greater peri-operative morbidity and increased post-operative length of stay appears to be a fairly consistent but not absolute finding in the obese and/or morbidly obese patients in the studies examined (Table 1). In the studies that document a higher morbidity in obese patients, wound related and infectious complications appear to predominate[35-38]. In one study, obese patients surprisingly did not require prolonged ventilatory support as compared to non-obese patients[39].

The differences seen in peri-operative morbidity amongst the different studies can potentially be explained by the heterogeneity amongst the obese and morbidly obese patients in that co-morbid conditions were not taken into consideration. Several studies attempted to take into account these co-morbid conditions. One group examined obesity along with the presence of coronary artery disease, and hypertension and calculated patients’ risk of post-operative events. The presence of obesity and diabetes appeared to be the strongest predictors of post-operative events[35]. The presence of cardiovascular risk factors however did not alter the peri-operative risk[35]. Similarly, Nair *et al*[40] examined the combination of several pre-operative risk factors that included obesity and diabetes to create a risk score and tested its ability to predict post-operative outcomes. Compared to the prior study, they found no difference in pre-operative morbidity and length of stay between the low risk and high-risk groups. Neither study found that these conditions affected short-term survival.

Cardiovascular events are a significant cause of morbidity in the post liver transplant patients, which maybe related to the higher prevalence of risk factors associated with the metabolic syndrome such as hypertension and hyperlipidemia in these patients[41]. A similar small study also found an increased risk of cardiovascular events in post liver transplant patients although this did not seem to correlate with obesity as the normal weight cohort had a similar rate of cardiovascular events[42]. A more recent, larger study using the OPTN database attempted to identify predictors of early cardiovascular events[43]. A total of 1576 deaths in the first 30 d post transplant were identified out of 54697 liver transplant recipients of which 42.1% were secondary to cardiovascular events. Surprising, obesity and complications of the metabolic syndrome were not found to be independent predictors of early cardiovascular mortality. Several other recipient factors were found to be significant predictors including pre-operative hospitalization, ICU and ventilator status, and the presence of portal vein thrombosis. Interestingly, Ayala *et al*[44] also found that obesity was a risk factor for pre-transplant portal vein thrombosis.

***Long-term outcomes***

The long-term outcomes of patients with obesity and morbid obesity have yet to be fully determined. One would assume that persistence of obesity and the metabolic syndrome post transplant would clearly put these patients at higher risk for developing serious cardiovascular disease including myocardial infarction and stroke. In 2002, Nair *et al*[45] published a review of the UNOS database from 1988 to 1996 comparing outcomes following liver transplant for patients that were obese, severely obese, and morbidly obese. A total of 18172 patients were examined and the authors found an increased risk of primary non-function and an increased risk of mortality at 30 d, 1 year, 2 years, and 5 years in the morbidly obese group. The severely obese group also had an increased risk of mortality at 5 years. All obese patients (BMI > 30) had an increased risk of death from cardiovascular events[45]. This led to the recommendation by the American Association for the Study of Liver Disease (AASLD) thatmorbid obesity was a contraindication to liver transplant[46]. Similarly, in 2003, Rustgi *et al*[47]published their analysis of the UNOS database from 1992 to 2000 examining a total of 26920 patients. In this study, patients with BMI ≥ 40 were found to be at increased risk of post-transplant death.

Conversely, a more recent publication examining the SRTR database from 2004 to 2011 identified 38194 recipients of which 8196 were considered obese. Unlike the review by Nair *et al*, they found no risk of increase mortality across the different categories of obese patients as compared to the control group. In fact, the authors found a protective affect of overweight male recipients but not female recipients with BMIs ranging between 25 and 35[48]. Another center also recently examined a very similar cohort of patients (SRTR database from 2007-2011) and also confirmed no difference in short-term outcomes. They, however, noted increased resource utilization by patient with BMIs ≥ 40 with more patients disabled in the pre-operative setting and longer post operative hospital stays[49].

Several single center studies have also documented long term outcomes. One of the largest series examined 1325 patients from Leeds, United Kingdom and the authors report no significant difference in graft and patient survival up to 10 years post transplant[37]. Another large single center study found an increased rate of the metabolic syndrome in their post transplant patients with BMIs ≥ 38, however, this did not correlate with poor 3 year outcomes[50]. A smaller study from Ireland also found no difference in long-term survival between their obese patients and non-obese patients [36]. Conversely, a study that examined outcomes over an extended period of time, dividing patients into different eras, found a consistent improvement in outcomes over time. However, in all eras, survival of the morbidly obese patients was worse, and morbid obesity was an independent predictor of death[51]. Interestingly, the risk of morbid obesity appeared to be exacerbated in the MELD era in this study with the poorest long-term survival seen in morbidly obese patients with MELD 22. A Danish group also had similar poor outcomes for their obese group[52]. Another single center study which examined long term outcomes (≥ 5 years) and noticed a significant decline in both graft and patient survival at 5 years despite similar outcomes at 3 years[53].

Studies that do demonstrate poor long-term outcomes associated with obesity have been criticized by the fact that they do not take into account malnutrition, low albumin levels and ascites. In one study, conventional BMI appears to be able to be mitigated by conversion to modified BMI that takes into account low albumin levels and fluid accumulation. When converted to a modified BMI (calculated by multiplying the serum albumin by the BMI), there was no difference in long-term survival of the different groups[38]. Similarly, Leonard *et al*[54] found that when correcting BMI for ascites, up to 20% of patients moved to a lower BMI category. Furthermore, the corrected BMI was not a predictor of poor long-term outcomes.

The inconsistency in results reported from different centers would suggest that patient selection plays a critical role in the outcomes of obese patients after transplant. The more recent trend in better outcomes may reflect better patient selection and improved care in the more recent era. However, more long-term data looking at 5 years and beyond are needed in order to adequately characterize the long-term risk to obese and morbidly obese patients.

***Recurrent disease in obese patients following liver transplantation***

The risk of recurrent NAFLD in post transplant patients has been documented and ranges between 25%-60%[55-58]. In one study, 39% of recipients transplanted for NAFLD had either recurrent NAFLD or NASH with the strongest independent predictors of recurrence being high pre transplant and post transplant BMIs. The presence of recurrent disease, however, did not appear to affect overall survival at least in the short term[56]. Similarly, patients transplanted for cryptogenic cirrhosis (of which several of the patients were believed to have NASH) have also been shown to develop NAFLD or NASH in the post transplant setting[59]. A more recent study examined the prevalence of post liver transplant NAFLD in patients transplanted for non-NAFLD related liver disease and found steatosis in 40% of patients[60]. BMI pre- and post-transplant appeared to correlate with the risk of developing post transplant steatohepatitis. Commonly used immunosuppressive medications such as steroids and calcineurin inhibitors could be potential factors contributing to insulin resistance/hyperglycemia, hyperlipidemia, and hypertension. In fact, exposure to a high total dosage of glucocorticoids has been associated with the development of NASH[61]

The association between chronic HCV infection and post transplant diabetes is well known. HCV appears to be partially responsible for inducing insulin resistance and diabetes mellitus. Unfortunately, the presence of diabetes mellitus portends a bad outcome with patients suffering from an accelerated progression to fibrosis leading to poor graft and patient survival[62].

Obesity also appears to affect recurrence of HCC. In a study by Mathur *et al*[63], the authors demonstrate a doubling in recurrence rates of HCC in both overweight and obese patients as compared to a lean group of patients following liver transplant. Similarly, patients with BMI > 30 were more prone to develop recurrence of HCC.

**Special Circumstances**

***Bariatric surgery prior to liver transplantation: Lessons learned from the jejunal-ileal bypass surgery***

There is no question that a prior history of upper abdominal surgery can increase the risk of peri-operative complication rate at the time of liver transplant. Abdominal scarring and adhesions can increase the complexity of the initial hepatectomy. In addition, vascularization of these adhesions from portal hypertension can result in greater blood loss. Many morbidly obese patients have attempted weight loss surgery prior to transplantation which puts the remnant stomach at risk for devascularization and luminal perforations.

The jejunoileal bypass (JIB) was a bariatric procedure that was performed with high frequency in the 1960 and1970s. This weight loss procedure consisted of dividing and anastomosing the first 35 centimeters of proximal jejunum to the terminal 10 centimeters of ileum in an end-to-side or end-to-end fashion[64]. Although this procedure was effective in causing malabsorption and weight loss, it also carried the complication of chronic liver disease and in some cases acute liver failure[65].

There have several reports that have documented the feasibility of performing liver transplants in patients who had previously undergone a JIB. Although the reports were small series, they documented that transplant was feasible with reasonable patient outcomes. In all cases, reversal of the bypass appears to be critical for the prevention of recurrent disease in most patients[66,67]. More recently, there have been several reports of patients requiring transplant after a biliopancreatic diversion (Scopinaro procedure or duodenal switch) from massive steatosis and sub-fulminant hepatic failure[68,69]

A recent survey of transplant centers in Belgium identified patients that had undergone liver transplant after bariatric surgery. They identified 10 patients listed for liver transplantation with a mean time to wait listing post bariatric surgery of 5 years. The majority of the patients (9 of 10) had undergone biliopancreatic diversion. Of the 10 patients, 7 were transplanted, 2 died waiting for transplant, and one was still waiting at the time of publication. Of the 7 patients transplanted, 4 patients were still alive. One of the 4 patients required retransplantation at 10 months due to rapid recurrence of liver disease. Although, liver transplantation can salvage patients with post bariatric surgery liver failure, outcomes appear to be poor and bariatric patients should be monitored closely for liver dysfunction following surgery[70].

***Bariatric surgery in conjunction with or after liver transplantation***

An attempt at bariatric surgery is appropriate for patients with early stage liver disease[71], but is never indicated in patients with advanced stage liver disease or cirrhosis. For many of these patients, continued long-term obesity post transplant will undoubtedly increase patients’ risk for long term complications associated with the metabolic syndrome. The risk obesity poses to the recurrence of NASH and HCV are also now coming to light. For many post-transplant patients, diet and exercise is rarely enough to incur significant, sustainable weight loss. Bariatric surgery has taken on many different forms (*e.g.*, gastric bypass, sleeve gastrectomy, gastric band) all of which have varying rates of technical complexity, associated complications, and effectiveness in terms of weight loss.

Several groups have documented the safety of performing bariatric surgery on post liver transplant patients either in small studies or case reports. An initial report by Duchini and Brunson documented that roux-en-Y gastric bypass (RYGB) could be safely performed in post liver transplant patients[72]. This study was further supported by larger studies by Al-Nowaylati *et al*[73]and Tichansky *et al*[74]. Although RYGB was effective in inducing weight loss, this did not come without risk. Complications post bariatric surgery included dumping, wound infections, and in one severe case, multi-system organ failure and death. One patient required reversal due to intractable malnutrition and gastrojejunal ulcers. Other groups have also shown that a sleeve gastrectomy can be performed safely and is effective in inducing weight loss in the post liver transplant patient[75,76].

Due to the increased technical complexity secondary to adhesions and complications related to long-term immunosuppression, some groups have attempted bariatric surgery at the time of transplant. In an initial report, Campsen *et al*[77] reported safely performing a gastric band in patients immediately after the new liver was transplanted. In a similar approach, Heimbach *et al*[78] from the Mayo Clinic reported their initial experience with performing the gastric sleeve at the time of liver transplant. This was chosen over the gastric band due to increased efficacy in inducing weight loss and the fact that there was no need for a foreign body in an immunosuppressed patient. In their initial report of 7 patients that underwent a combined liver transplant-sleeve gastrectomy, all patient attained weight loss and none developed post liver transplant diabetes or hepatic steatosis. However, one patient did have excessive weight loss and one patient leaked from the gastric staple line. There were no graft failures or deaths in the combined groups.

***Living donor liver transplantation***

Adult-to-adult living donor liver transplantation (LDLT) has been shown to have outcomes equivalent to deceased donor liver transplantation especially in regions where organ donation is scarce. Death on the waiting list which can be as high as 20% at some United States centers. It is well documented that there is a significant survival advantage to patients transplanted with living donors as compared to those patients that wait on the deceased donor list when compared to time of listing by preventing[79]. In other parts of the world where deceased donation is non-existent, LDLT is the only option for patients with ESLD. Appropriate size matching of the liver graft from the living donor with the recipient is essential for success with most programs using a cutoff graft weight to recipient weight ratio (GRWR) of 0.8. Successful LDLT has been performed with lower GRWR[80] and there is a resurgence of left lobe grafts in the Western world[81].

Appropriate matching of donors with obese recipients can be especially challenging in the setting of LDLT especially when using the common cutoff of 0.8 for the GRWR. Whether this ratio is appropriate in the setting of obesity has yet to be determined. There are no studies that examine the morbidly obese population, and studies examining LDLT in the setting of obesity are scarce. The largest study by Gunay *et al*[82]examined 380 patients who underwent LDLT of which 74 were considered obese (BMI ≥ 30). No patients were morbidly obese (BMI > 40). Although the obese patients had a harder time finding suitable living donors, the complication rate, graft survival, and patient survival were all similar when comparing the obese recipients to either the overweight or normal weight recipients[82]. A smaller study of 7 patients with NASH of which 6 of the patients were obese also demonstrated that LDLT was feasible, but again these patients appeared to have a more difficult time identifying suitable donors[83]. Further studies are needed to address long-term outcomes of LDLT and also to further investigate the applicability of a GRWR of ≤ 0.8 in the setting of morbid obesity.

**Our Experience with Morbid Obesity and Liver Transplantation at Ochsner Medical Center**

Over the last few years, Ochsner medical center has grown to become one of the largest liver transplant programs in the United States performing 196 liver transplants in 2014. Due to its geographic location in the South Eastern corridor of the United States, the program has a vast experience with liver transplantation of the morbidly obese patient. In our experience, it is important to make sure that the morbidly obese patients are properly cleared from a cardiopulmonary perspective as many of them can have occult coronary disease and/or pulmonary hypertension. From a technical perspective, line placement and exposure during transplant can be challenging and we have moved to using a Thompson retractor with special bariatric blades to aid in exposure.

A chart review of primary liver or combined liver-kidney transplants was performed between September 2005 and December 2008 of which 255 adult transplants were identified. A comparison of morbidly obese patients (*n* = 34) versus a control group (*n* = 221) of non-morbidly obese patients was performed and several characteristics including 30 d and 1 year graft and patient survival, length of stay, and 30 d re-operation rate were recorded. Based on our data, morbidly obese patients had longer median length of stays (19 d *vs* 13 d), but 30-d re-operation rates were not higher in the morbidly obese group. Thirty day and 1-year graft and patient survival were equivalent[84].

**Conclusion**

There are multiple indications for liver transplantation in the obese patient, but NAFLD is the most common. Obese patients appear to be at higher risk for peri-operative complications and length of stay post-transplant is longer which potentially can increase the global health care cost to managing these patients. However, this does not appear to impact both short and long term outcomes following transplant. The impact of obesity and the metabolic syndrome on long-term outcomes remains to be determined but these patients are at risk for recurrent steatohepatitis. Weight reduction post transplant is likely to be effective in avoiding complications of the metabolic syndrome including post transplant diabetes and steatosis. Weight loss surgery appears to be advantageous at the time of transplant since it avoids the need for an additional surgery and also avoids the potential for increased complications due to abdominal scarring and long-term immunosuppression. Appropriate patient selection is critical for minimizing complications and obtaining optimal short and long-term outcomes.

**References**

1 **Nguyen N**, Champion JK, Ponce J, Quebbemann B, Patterson E, Pham B, Raum W, Buchwald JN, Segato G, Favretti F. A review of unmet needs in obesity management. *Obes Surg* 2012; **22**: 956-966 [PMID: 22438220 DOI: 10.1007/s11695-012-0634-z]

2 **Ng M**, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullany EC, Biryukov S, Abbafati C, Abera SF, Abraham JP, Abu-Rmeileh NM, Achoki T, AlBuhairan FS, Alemu ZA, Alfonso R, Ali MK, Ali R, Guzman NA, Ammar W, Anwari P, Banerjee A, Barquera S, Basu S, Bennett DA, Bhutta Z, Blore J, Cabral N, Nonato IC, Chang JC, Chowdhury R, Courville KJ, Criqui MH, Cundiff DK, Dabhadkar KC, Dandona L, Davis A, Dayama A, Dharmaratne SD, Ding EL, Durrani AM, Esteghamati A, Farzadfar F, Fay DF, Feigin VL, Flaxman A, Forouzanfar MH, Goto A, Green MA, Gupta R, Hafezi-Nejad N, Hankey GJ, Harewood HC, Havmoeller R, Hay S, Hernandez L, Husseini A, Idrisov BT, Ikeda N, Islami F, Jahangir E, Jassal SK, Jee SH, Jeffreys M, Jonas JB, Kabagambe EK, Khalifa SE, Kengne AP, Khader YS, Khang YH, Kim D, Kimokoti RW, Kinge JM, Kokubo Y, Kosen S, Kwan G, Lai T, Leinsalu M, Li Y, Liang X, Liu S, Logroscino G, Lotufo PA, Lu Y, Ma J, Mainoo NK, Mensah GA, Merriman TR, Mokdad AH, Moschandreas J, Naghavi M, Naheed A, Nand D, Narayan KM, Nelson EL, Neuhouser ML, Nisar MI, Ohkubo T, Oti SO, Pedroza A, Prabhakaran D, Roy N, Sampson U, Seo H, Sepanlou SG, Shibuya K, Shiri R, Shiue I, Singh GM, Singh JA, Skirbekk V, Stapelberg NJ, Sturua L, Sykes BL, Tobias M, Tran BX, Trasande L, Toyoshima H, van de Vijver S, Vasankari TJ, Veerman JL, Velasquez-Melendez G, Vlassov VV, Vollset SE, Vos T, Wang C, Wang X, Weiderpass E, Werdecker A, Wright JL, Yang YC, Yatsuya H, Yoon J, Yoon SJ, Zhao Y, Zhou M, Zhu S, Lopez AD, Murray CJ, Gakidou E. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2014; **384**: 766-781 [PMID: 24880830 DOI: 10.1016/S0140-6736(14)60460-8]

3 **Ford ES**, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA* 2002; **287**: 356-359 [PMID: 11790215]

4 **Haffner S**, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. *Circulation* 2003; **108**: 1541-1545 [PMID: 14517149 DOI: 10.1161/01.CIR.0000088845.17586.EC]

5 **Ong JP**, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. *Clin Liver Dis* 2007; **11**: 1-16, vii [PMID: 17544968 DOI: 10.1016/j.cld.2007.02.009]

6 **Brunt EM**, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. *World J Gastroenterol* 2010; **16**: 5286-5296 [PMID: 21072891]

7 **Browning JD**, Horton JD. Molecular mediators of hepatic steatosis and liver injury. *J Clin Invest* 2004; **114**: 147-152 [PMID: 15254578 DOI: 10.1172/JCI22422]

8 **Romeo S**, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet* 2008; **40**: 1461-1465 [PMID: 18820647 DOI: 10.1038/ng.257]

9 **Williams CD**, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. *Gastroenterology* 2011; **140**: 124-131 [PMID: 20858492 DOI: 10.1053/j.gastro.2010.09.038]

10 **Browning JD**, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004; **40**: 1387-1395 [PMID: 15565570 DOI: 10.1002/hep.20466]

11 **Weston SR**, Leyden W, Murphy R, Bass NM, Bell BP, Manos MM, Terrault NA. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. *Hepatology* 2005; **41**: 372-379 [PMID: 15723436 DOI: 10.1002/hep.20554]

12 **Argo CK**, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. *Clin Liver Dis* 2009; **13**: 511-531 [PMID: 19818302 DOI: 10.1016/j.cld.2009.07.005]

13 **Sorrentino P**, Terracciano L, D'Angelo S, Ferbo U, Bracigliano A, Vecchione R. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. *Am J Gastroenterol* 2010; **105**: 336-344 [PMID: 19861959 DOI: 10.1038/ajg.2009.587]

14 **Ong J**, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, Boparai N. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. *Liver Transpl* 2001; **7**: 797-801 [PMID: 11552214 DOI: 10.1053/jlts.2001.24644]

15 **Bellentani S**, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. *Dig Dis* 2010; **28**: 155-161 [PMID: 20460905 DOI: 10.1159/000282080]

16 **Shneider BL**, González-Peralta R, Roberts EA. Controversies in the management of pediatric liver disease: Hepatitis B, C and NAFLD: Summary of a single topic conference. *Hepatology* 2006; **44**: 1344-1354 [PMID: 17058223 DOI: 10.1002/hep.21373]

17 **Schwimmer JB**, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. *Pediatrics* 2006; **118**: 1388-1393 [PMID: 17015527 DOI: 10.1542/peds.2006-1212]

18 **Loomba R**, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. *Hepatology* 2009; **50**: 1282-1293 [PMID: 19637286 DOI: 10.1002/hep.23119]

19 **Petersen KF**, Dufour S, Feng J, Befroy D, Dziura J, Dalla Man C, Cobelli C, Shulman GI. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. *Proc Natl Acad Sci USA* 2006; **103**: 18273-18277 [PMID: 17114290 DOI: 10.1073/pnas.0608537103]

20 **Schwimmer JB**, McGreal N, Deutsch R, Finegold MJ, Lavine JE. Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. *Pediatrics* 2005; **115**: e561-e565 [PMID: 15867021 DOI: 10.1542/peds.2004-1832]

21 **Holterman AX**, Guzman G, Fantuzzi G, Wang H, Aigner K, Browne A, Holterman M. Nonalcoholic fatty liver disease in severely obese adolescent and adult patients. *Obesity* (Silver Spring) 2013; **21**: 591-597 [PMID: 23592668 DOI: 10.1002/oby.20174]

22 **Feldstein AE**, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. *Gut* 2009; **58**: 1538-1544 [PMID: 19625277 DOI: 10.1136/gut.2008.171280]

23 **Bugianesi E**, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. *Gastroenterology* 2002; **123**: 134-140 [PMID: 12105842]

24 **Caldwell SH**, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. *J Hepatol* 2004; **40**: 578-584 [PMID: 15030972 DOI: 10.1016/j.jhep.2004.02.013]

25 **Wolk A**, Gridley G, Svensson M, Nyrén O, McLaughlin JK, Fraumeni JF, Adam HO. A prospective study of obesity and cancer risk (Sweden). *Cancer Causes Control* 2001; **12**: 13-21 [PMID: 11227921]

26 **Dongiovanni P**, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. *World J Gastroenterol* 2014; **20**: 12945-12955 [PMID: 25278690 DOI: 10.3748/wjg.v20.i36.12945]

27 **Hernandez-Alejandro R**, Croome KP, Drage M, Sela N, Parfitt J, Chandok N, Marotta P, Dale C, Wall W, Quan D. A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma. *World J Gastroenterol* 2012; **18**: 4145-4149 [PMID: 22919246 DOI: 10.3748/wjg.v18.i31.4145]

28 **Reddy SK**, Steel JL, Chen HW, DeMateo DJ, Cardinal J, Behari J, Humar A, Marsh JW, Geller DA, Tsung A. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. *Hepatology* 2012; **55**: 1809-1819 [PMID: 22183968 DOI: 10.1002/hep.25536]

29 **Braunfeld MY**, Chan S, Pregler J, Neelakanta G, Sopher MJ, Busuttil RW, Csete M. Liver transplantation in the morbidly obese. *J Clin Anesth* 1996; **8**: 585-590 [PMID: 8910182]

30 **Keeffe EB**, Gettys C, Esquivel CO. Liver transplantation in patients with severe obesity. *Transplantation* 1994; **57**: 309-311 [PMID: 8310529]

31 **Nair S**, Cohen DB, Cohen MP, Tan H, Maley W, Thuluvath PJ. Postoperative morbidity, mortality, costs, and long-term survival in severely obese patients undergoing orthotopic liver transplantation. *Am J Gastroenterol* 2001; **96**: 842-845 [PMID: 11280562 DOI: 10.1111/j.1572-0241.2001.03629.x]

32 **Sawyer RG**, Pelletier SJ, Pruett TL. Increased early morbidity and mortality with acceptable long-term function in severely obese patients undergoing liver transplantation. *Clin Transplant* 1999; **13**: 126-130 [PMID: 10081649]

33 **Pelletier SJ**, Maraschio MA, Schaubel DE, Dykstra DM, Punch JD, Wolfe RA, Port FK, Merion RM. Survival benefit of kidney and liver transplantation for obese patients on the waiting list. *Clin Transpl* 2003; 77-88 [PMID: 15387099]

34 **Pelletier SJ**, Schaubel DE, Wei G, Englesbe MJ, Punch JD, Wolfe RA, Port FK, Merion RM. Effect of body mass index on the survival benefit of liver transplantation. *Liver Transpl* 2007; **13**: 1678-1683 [PMID: 18044787 DOI: 10.1002/lt.21183]

35 **Dare AJ**, Plank LD, Phillips AR, Gane EJ, Harrison B, Orr D, Jiang Y, Bartlett AS. Additive effect of pretransplant obesity, diabetes, and cardiovascular risk factors on outcomes after liver transplantation. *Liver Transpl* 2014; **20**: 281-290 [PMID: 24395145 DOI: 10.1002/lt.23818]

36 **Hade AM**, Shine AM, Kennedy NP, McCormick PA. Both under-nutrition and obesity increase morbidity following liver transplantation. *Ir Med J* 2003; **96**: 140-142 [PMID: 12846275]

37 **Hakeem AR**, Cockbain AJ, Raza SS, Pollard SG, Toogood GJ, Attia MA, Ahmad N, Hidalgo EL, Prasad KR, Menon KV. Increased morbidity in overweight and obese liver transplant recipients: a single-center experience of 1325 patients from the United Kingdom. *Liver Transpl* 2013; **19**: 551-562 [PMID: 23408499 DOI: 10.1002/lt.23618]

38 **Tanaka T**, Renner EL, Selzner N, Therapondos G, Lilly LB. The impact of obesity as determined by modified body mass index on long-term outcome after liver transplantation: Canadian single-center experience. *Transplant Proc* 2013; **45**: 2288-2294 [PMID: 23953540 DOI: 10.1016/j.transproceed.2012.11.009]

39 **Werneck M**, Afonso RC, Coelho GR, Sboarini C, Coelho MP, Thomé T, Lisboa LF, Ferraz Neto BH. Obese and nonobese recipients had similar need for ventilatory support after liver transplantation. *Transplant Proc* 2011; **43**: 165-169 [PMID: 21335178 DOI: 10.1016/j.transproceed.2010.12.004]

40 **Nair S**, Vanatta JM, Arteh J, Eason JD. Effects of obesity, diabetes, and prior abdominal surgery on resource utilization in liver transplantation: a single-center study. *Liver Transpl* 2009; **15**: 1519-1524 [PMID: 19877252 DOI: 10.1002/lt.21889]

41 **Johnston SD**, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. *Transplantation* 2002; **73**: 901-906 [PMID: 11923689]

42 **Mazuelos F**, Abril J, Zaragoza C, Rubio E, Moreno JM, Turrión VS, Cuervas-Mons V. Cardiovascular morbidity and obesity in adult liver transplant recipients. *Transplant Proc* 2003; **35**: 1909-1910 [PMID: 12962844]

43 **VanWagner LB**, Lapin B, Levitsky J, Wilkins JT, Abecassis MM, Skaro AI, Lloyd-Jones DM. High early cardiovascular mortality after liver transplantation. *Liver Transpl* 2014; **20**: 1306-1316 [PMID: 25044256 DOI: 10.1002/lt.23950]

44 **Ayala R**, Grande S, Bustelos R, Ribera C, García-Sesma A, Jimenez C, Moreno E, Martínez-López J. Obesity is an independent risk factor for pre-transplant portal vein thrombosis in liver recipients. *BMC Gastroenterol* 2012; **12**: 114 [PMID: 22909075 DOI: 10.1186/1471-230X-12-114]

45 **Nair S**, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. *Hepatology* 2002; **35**: 105-109 [PMID: 11786965 DOI: 10.1053/jhep.2002.30318]

46 **Murray KF**, Carithers RL. AASLD practice guidelines: Evaluation of the patient for liver transplantation. *Hepatology* 2005; **41**: 1407-1432 [PMID: 15880505 DOI: 10.1002/hep.20704]

47 **Rustgi VK**, Marino G, Rustgi S, Halpern MT, Johnson LB, Tolleris C, Taddei TH. Impact of body mass index on graft failure and overall survival following liver transplant. *Clin Transplant* 2004; **18**: 634-637 [PMID: 15516235 DOI: 10.1111/j.1399-0012.2004.00141.x]

48 **Orci LA**, Majno PE, Berney T, Morel P, Mentha G, Toso C. The impact of wait list body mass index changes on the outcome after liver transplantation. *Transpl Int* 2013; **26**: 170-176 [PMID: 23199077 DOI: 10.1111/tri.12017]

49 **Singhal A**, Wilson GC, Wima K, Quillin RC, Cuffy M, Anwar N, Kaiser TE, Paterno F, Diwan TS, Woodle ES, Abbott DE, Shah SA. Impact of recipient morbid obesity on outcomes after liver transplantation. *Transpl Int* 2015; **28**: 148-155 [PMID: 25363625 DOI: 10.1111/tri.12483]

50 **Perez-Protto SE**, Quintini C, Reynolds LF, You J, Cywinski JB, Sessler DI, Miller C. Comparable graft and patient survival in lean and obese liver transplant recipients. *Liver Transpl* 2013; **19**: 907-915 [PMID: 23744721 DOI: 10.1002/lt.23680]

51 **Dick AA**, Spitzer AL, Seifert CF, Deckert A, Carithers RL, Reyes JD, Perkins JD. Liver transplantation at the extremes of the body mass index. *Liver Transpl* 2009; **15**: 968-977 [PMID: 19642131 DOI: 10.1002/lt.21785]

52 **Hillingsø JG**, Wettergren A, Hyoudo M, Kirkegaard P. Obesity increases mortality in liver transplantation--the Danish experience. *Transpl Int* 2005; **18**: 1231-1235 [PMID: 16221152 DOI: 10.1111/j.1432-2277.2005.00206.x]

53 **Conzen KD**, Vachharajani N, Collins KM, Anderson CD, Lin Y, Wellen JR, Shenoy S, Lowell JA, Doyle MB, Chapman WC. Morbid obesity in liver transplant recipients adversely affects longterm graft and patient survival in a single-institution analysis. *HPB* (Oxford) 2015; **17**: 251-257 [PMID: 25322849 DOI: 10.1111/hpb.12340]

54 **Leonard J**, Heimbach JK, Malinchoc M, Watt K, Charlton M. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. *Am J Transplant* 2008; **8**: 667-672 [PMID: 18294163 DOI: 10.1111/j.1600-6143.2007.02100.x]

55 **Bhagat V**, Mindikoglu AL, Nudo CG, Schiff ER, Tzakis A, Regev A. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. *Liver Transpl* 2009; **15**: 1814-1820 [PMID: 19938128 DOI: 10.1002/lt.21927]

56 **Dureja P**, Mellinger J, Agni R, Chang F, Avey G, Lucey M, Said A. NAFLD recurrence in liver transplant recipients. *Transplantation* 2011; **91**: 684-689 [PMID: 21248661 DOI: 10.1097/TP.0b013e31820b6b84]

57 **Kim WR**, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. *Transplantation* 1996; **62**: 1802-1805 [PMID: 8990367]

58 **Molloy RM**, Komorowski R, Varma RR. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. *Liver Transpl Surg* 1997; **3**: 177-178 [PMID: 9346733]

59 **Contos MJ**, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, Fisher RA, Ham J, Sanyal AJ. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. *Liver Transpl* 2001; **7**: 363-373 [PMID: 11303298 DOI: 10.1053/jlts.2001.23011]

60 **Lim LG**, Cheng CL, Wee A, Lim SG, Lee YM, Sutedja DS, Da Costa M, Prabhakaran K, Wai CT. Prevalence and clinical associations of posttransplant fatty liver disease. *Liver Int* 2007; **27**: 76-80 [PMID: 17241384 DOI: 10.1111/j.1478-3231.2006.01396.x]

61 **Matsumoto T**, Yamasaki S, Arakawa A, Abe K, Abe H, Kon K, Kobayashi S, Takasaki Y. Exposure to a high total dosage of glucocorticoids produces non-alcoholic steatohepatits. *Pathol Int* 2007; **57**: 388-389 [PMID: 17539971 DOI: 10.1111/j.1440-1827.2007.02112.x]

62 **Gane EJ**. Diabetes mellitus following liver transplantation in patients with hepatitis C virus: risks and consequences. *Am J Transplant* 2012; **12**: 531-538 [PMID: 22123496 DOI: 10.1111/j.1600-6143.2011.03854.x]

63 **Mathur A**, Franco ES, Leone JP, Osman-Mohamed H, Rojas H, Kemmer N, Neff GW, Rosemurgy AS, Alsina AE. Obesity portends increased morbidity and earlier recurrence following liver transplantation for hepatocellular carcinoma. *HPB* (Oxford) 2013; **15**: 504-510 [PMID: 23750492 DOI: 10.1111/j.1477-2574.2012.00602.x]

64 **Singh D**, Laya AS, Clarkston WK, Allen MJ. Jejunoileal bypass: a surgery of the past and a review of its complications. *World J Gastroenterol* 2009; **15**: 2277-2279 [PMID: 19437570]

65 **Requarth JA**, Burchard KW, Colacchio TA, Stukel TA, Mott LA, Greenberg ER, Weismann RE. Long-term morbidity following jejunoileal bypass. The continuing potential need for surgical reversal. *Arch Surg* 1995; **130**: 318-325 [PMID: 7887801]

66 **Lowell JA**, Shenoy S, Ghalib R, Caldwell C, White FV, Peters M, Howard TK. Liver transplantation after jejunoileal bypass for morbid obesity. *J Am Coll Surg* 1997; **185**: 123-127 [PMID: 9249079]

67 **Markowitz JS**, Seu P, Goss JA, Yersiz H, Markmann JF, Farmer DG, Ghobrial RM, Goldstein LI, Martin P, Stribling R, Busuttil RW. Liver transplantation for decompensated cirrhosis after jejunoileal bypass: a strategy for management. *Transplantation* 1998; **65**: 570-572 [PMID: 9500634]

68 **Castillo J**, Fábrega E, Escalante CF, Sanjuan JC, Herrera L, Hernánz F, Martino E, Casafont F, Gómez Fleitas M. Liver transplantation in a case of steatohepatitis and subacute hepatic failure after biliopancreatic diversion for morbid obesity. *Obes Surg* 2001; **11**: 640-642 [PMID: 11594111]

69 **D'Albuquerque LA**, Gonzalez AM, Wahle RC, de Oliveira Souza E, Mancero JM, de Oliveira e Silva A. Liver transplantation for subacute hepatocellular failure due to massive steatohepatitis after bariatric surgery. *Liver Transpl* 2008; **14**: 881-885 [PMID: 18508357 DOI: 10.1002/lt.21472]

70 **Geerts A**, Darius T, Chapelle T, Roeyen G, Francque S, Libbrecht L, Nevens F, Pirenne J, Troisi R. The multicenter Belgian survey on liver transplantation for hepatocellular failure after bariatric surgery. *Transplant Proc* 2010; **42**: 4395-4398 [PMID: 21168706 DOI: 10.1016/j.transproceed.2010.07.010]

71 **Dallal RM**, Mattar SG, Lord JL, Watson AR, Cottam DR, Eid GM, Hamad G, Rabinovitz M, Schauer PR. Results of laparoscopic gastric bypass in patients with cirrhosis. *Obes Surg* 2004; **14**: 47-53 [PMID: 14980033 DOI: 10.1381/096089204772787284]

72 **Duchini A**, Brunson ME. Roux-en-Y gastric bypass for recurrent nonalcoholic steatohepatitis in liver transplant recipients with morbid obesity. *Transplantation* 2001; **72**: 156-159 [PMID: 11468551]

73 **Al-Nowaylati AR**, Al-Haddad BJ, Dorman RB, Alsaied OA, Lake JR, Chinnakotla S, Slusarek BM, Sampson BK, Ikramuddin S, Buchwald H, Leslie DB. Gastric bypass after liver transplantation. *Liver Transpl* 2013; **19**: 1324-1329 [PMID: 24039124 DOI: 10.1002/lt.23734]

74 **Tichansky DS**, Madan AK. Laparoscopic Roux-en-Y gastric bypass is safe and feasible after orthotopic liver transplantation. *Obes Surg* 2005; **15**: 1481-1486 [PMID: 16354531 DOI: 10.1381/096089205774859164]

75 **Butte JM**, Devaud N, Jarufe NP, Boza C, Pérez G, Torres J, Pérez-Ayuso RM, Arrese M, Martínez J. Sleeve gastrectomy as treatment for severe obesity after orthotopic liver transplantation. *Obes Surg* 2007; **17**: 1517-1519 [PMID: 18219781]

76 **Lin MY**, Tavakol MM, Sarin A, Amirkiai SM, Rogers SJ, Carter JT, Posselt AM. Safety and feasibility of sleeve gastrectomy in morbidly obese patients following liver transplantation. *Surg Endosc* 2013; **27**: 81-85 [PMID: 22752278 DOI: 10.1007/s00464-012-2410-5]

77 **Campsen J**, Zimmerman M, Shoen J, Wachs M, Bak T, Mandell MS, Kam I. Adjustable gastric banding in a morbidly obese patient during liver transplantation. *Obes Surg* 2008; **18**: 1625-1627 [PMID: 18704606 DOI: 10.1007/s11695-008-9633-5]

78 **Heimbach JK**, Watt KD, Poterucha JJ, Ziller NF, Cecco SD, Charlton MR, Hay JE, Wiesner RH, Sanchez W, Rosen CB, Swain JM. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. *Am J Transplant* 2013; **13**: 363-368 [PMID: 23137119 DOI: 10.1111/j.1600-6143.2012.04318.x]

79 **Shah SA**, Levy GA, Greig PD, Smith R, McGilvray ID, Lilly LB, Girgrah N, Cattral MS, Grant DR. Reduced mortality with right-lobe living donor compared to deceased-donor liver transplantation when analyzed from the time of listing. *Am J Transplant* 2007; **7**: 998-1002 [PMID: 17391140 DOI: 10.1111/j.1600-6143.2006.01692.x]

80 **Selzner M**, Kashfi A, Cattral MS, Selzner N, Greig PD, Lilly L, McGilvray ID, Therapondos G, Adcock LE, Ghanekar A, Levy GA, Renner EL, Grant DR. A graft to body weight ratio less than 0.8 does not exclude adult-to-adult right-lobe living donor liver transplantation. *Liver Transpl* 2009; **15**: 1776-1782 [PMID: 19938139 DOI: 10.1002/lt.21955]

81 **Botha JF**, Langnas AN, Campos BD, Grant WJ, Freise CE, Ascher NL, Mercer DF, Roberts JP. Left lobe adult-to-adult living donor liver transplantation: small grafts and hemiportocaval shunts in the prevention of small-for-size syndrome. *Liver Transpl* 2010; **16**: 649-657 [PMID: 20440774 DOI: 10.1002/lt.22043]

82 **Gunay Y**, Guler N, Dayangac M, Taskesen F, Yaprak O, Emek E, Akyildiz M, Altaca G, Yuzer Y, Tokat Y. Living donor liver transplantation for obese patients: challenges and outcomes. *Liver Transpl* 2014; **20**: 311-322 [PMID: 24243642 DOI: 10.1002/lt.23794]

83 **Tanaka T**, Sugawara Y, Tamura S, Kaneko J, Takazawa Y, Aoki T, Hasegawa K, Sakamoto Y, Yamashiki N, Kokudo N. Living donor liver transplantation for non-alcoholic steatohepatitis: A single center experience. *Hepatol Res* 2014; **44**: E3-E10 [PMID: 23834427 DOI: 10.1111/hepr.12200]

84 **Carmody IC**, Reichman TW, Bohorquez H, Cohen AJ, Bruce DS, Therapondos G, Girgrah N, Joshi S, Loss GE. Liver transplantation at the Ochsner Clinic: programmatic expansion and outcomes improvement. *Clin Transpl* 2012; 111-120 [PMID: 23721014]

**P-Reviewer:** Ding MX, Dorobantu B, Kapoor S, Zeng Z, Vespasiani-Gentilucci U

**S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Table 1 Outcomes following liver transplantation in obese patients (2000-present)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Patients (*n*)** | **Classification**  **(BMI)** | **LOS** | **PerioperativeComplication**  **Rate** | **Graft Survival** | **Patient**  **Survival** |
| Nair *et al*[21]*,* 2001 | 121 | NW *vs*  OB (27.8-31.1 M and 27.3-32.3 F)  MO (> 31.1 M and > 32.3 F) | in MO | in MO | NA | NoD |
| Nair *et al*[45]*,* 2002,  (UNOS data) | 23675 | NW *vs*  SO (35.1-40)  MO (> 40) | NA | NA | NoD  (1 and 2 yr) |  in SO  (5 yr)   in MO  (1,2 and 5 yr) |
| Dare *et al*[35]*,* 2014 | 202 | NO (< 30) *vs* OB (≥ 30) |  in OB | in OB | NA | NoD |
| Tanaka *et al*[38]*,* 2013 | 507 | cBMI (≤ 40 *vs* 40)  mBMI (≤ 40 *vs* 40) | in MO  ND | NA |  in MO  NoD |  in MO  NoD |
| Hakeem *et al*[37]*,* 2013 | 1325 | NW *vs*  OW (25-29.9), OB (30-34.9)  MO (≥ 35) |  in OW and OB |  in OW and OB | NoD | NoD |
| Dick *et al*[38]*,* 2009 (UNOS data) | 73,538 | NW *vs*  MO (≥ 40) | in MO |  in MO | NA |  in MO |
| Perez-Protto *et al*[50]*,* 2013 | 230 | NW *vs*  OB (≥ 38) | NoD | NoD | NoD | NoD |
| Fujikawa *et al,* 2006 | 700 | NW *vs*  OW (25-29.9)  OB (≥ 30) | NoD | NoD | NoD | NoD |
| Hillingsø *et al*[52]*,* 2005 | 365 | NW *vs*  OB (> 30) | NoD | NoD | NA |  in OB |
| Conzen *et al*[53]*,* 2014 | 785 | NW *vs* MO (≥ 40) | NoD | NoD | NoD  (at 3 years)   in MO  (at 5 years) | NoD  (at 3 years)   in MO  (at 5 years) |
| Werneck *et al*[39]*,* 2011 | 136 | NW *vs*  OW (25-29.9)  OB (≥ 30) | NoD | NoD | NoD | NoD |
| Nair *et al*[40]*,* 2009 | 193 | NW *vs*  MO (≥ 40) | in MO | NA | NA | NoD |
| Singhal *et al*[49]*,* 2015,(SRTR) | 12,445 | NW *vs*  MO (≥ 40) | in MO | NA | NoD | NoD |
| Schaeffer *et al*, 2009 | 167 | NW *vs*  OB (> 35) | NA | in OB | NoD  (at 1 yr) | NoD  (at 1 yr) |

NR: Not available; NoD: No difference; NO: Non-obese; OW: Overweight; OB: Obese; SO: Severely obese; MO: Morbidly obese; BMI: Body mass index.